Last week, I told you about a new opportunity to make a ton of money in the psychedelics space.
Since that article, one of my early psychedelics picks skyrocketed from $0.71 to $1.74 a share.
That’s a 145% gain in just seven trading days.
And that, dear reader, is how fortunes are made.
I know, because this is exactly what I did in the renewable energy space back in 2006, and it’s what I did more recently in the cannabis space: getting in early and cashing out for huge gains after the herd comes running.
The result?
Take a look at my three biggest winners in the cannabis space…
- Canopy Growth Corporation (TSX: WEED): 3,015.5%.
- Aphria, Inc. (TSX: APHA): 1,174.3%.
- OrganiGram Holdings (TSX-V: OGI): 1,185%.
Those who made simple $10,000 investments in each of those stocks, walked away with a total of $540,000.
That’s more than a half-million dollars on just three stocks!
Of course, those gains are yesterday’s news, and now we’ve moved on to…
The Next Big Thing: Psychedelics
As I noted in my article last week, the U.S. has a very serious mental illness and drug addiction crisis that’s only being exacerbated by this pandemic.
New reports from mental health research facilities, universities, and even the UN indicate massive spikes in new diagnoses of depression, anxiety, and addiction over the past two months.
Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.
A horrible result of this pandemic to be sure but a huge opportunity for a select group of companies that are providing new and much better therapies for a variety of mental health issues. And many of these companies are testing psychedelic therapies that are showing amazing results — so amazing, in fact, that the FDA is now fast-tracking the clinical trials for many of these new drugs and therapies.
One company that has a very clear early-mover advantage here is Champignon Brands (CSE: SHRM) (OTCBB: SHRMF).
This is the company I recommended to readers of my Green Chip Stocks community last week and has since delivered gains in excess of 145%.
Champignon Brands is currently pursuing the development and commercialization of certain psychedelic medicines that are capable of treating depression, PTSD, and addiction.
One thing Champignon has going for it right now is that it currently has a fully operational psychedelics medicine clinic in Canada, which happens to have 16 months of operating history. It’s actually the only one that’s been approved by Health Canada regulators, too, and has administered more than 1,500 treatments to more than 300 patients.
This is what I’m talking about when I say “first-mover advantage.”
Now while this stock has already made us a lot of money, this thing still has plenty of steam left in it. In fact, I’m seeing price targets as high as $5 right now, which would mean a potential gain of 604% based on the price we initially got in at.
Make no mistake: We plan on making a lot more on this one in the coming months. And of course, I’ll provide more updates on Champignon, as well as a few other psychedelics plays I’m looking at, in the coming weeks.
So click here to ensure that you get these dedicated updates and new recommendations.
To a new way of life and a new generation of wealth…
Jeff Siegel
Check us out on YouTube!
@JeffSiegel on Twitter
Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor’s page.
Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.
